Cliff Asness’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.68M Buy
+889,633
New +$1.74M ﹤0.01% 2770
2025
Q4
– Sell
-18,026
Closed -$68.3K – 3574
2025
Q3
$68.3K Sell
18,026
-195,211
-92% -$571K ﹤0.01% 3401
2025
Q2
$529K Buy
213,237
+159,115
+294% +$307K ﹤0.01% 2592
2025
Q1
$83.9K Buy
+54,122
New +$113K ﹤0.01% 3040
2024
Q4
– Sell
-15,692
Closed -$68.3K – 2875
2024
Q3
$68.3K Buy
+15,692
New +$85.4K ﹤0.01% 2688
2022
Q3
– Sell
-18,663
Closed -$46K – 2200
2022
Q2
$46K Buy
18,663
+4,773
+34% +$11.1K ﹤0.01% 2138
2022
Q1
$38K Buy
+13,890
New +$50.7K ﹤0.01% 2190

Other funds holding BDTX

Cliff Asness's BDTX Position: Q3 2026 in Review

Cliff Asness opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 889,633 shares worth $1.68M. The stake represents ﹤0.01% of the portfolio and ranks #2770 among its holdings. This is a return to the name: Cliff Asness previously reported a position in BDTX as recently as Q3 2025.

Cliff Asness first reported a position in BDTX in Q1 2022 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Cliff Asness held 889,633 shares of Black Diamond Therapeutics worth $1.68M as of Q3 2026.
  • Black Diamond Therapeutics was a new Cliff Asness position in Q3 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q3 2026, its #2770 holding.
  • Cliff Asness first reported a position in Black Diamond Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.